Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.00
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line

Wed, 27th Mar 2024 16:13

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Spectra Systems Corp - Providence, Rhode Island-based authentication technology provider - Reports revenue in 2023 edged up to USD20.2 million from USD19.6 million the year prior. Net income was USD6.0 million, slightly lower than USD6.1 million last time, with diluted earnings per share of 0.13 pence compared to 0.12p. Pays annual dividend of USD0.116 per share, up from USD0.115. Says cash position "remains strong", with cash generation driven by sensor development milestones and prepayments, record sales of covert materials to a central bank, and strong optical materials sales. Believes "that the company is on track to achieve record earnings in 2024."

----------

Infrastructure India PLC - infrastructure fund investing directly into assets in India - Says pretax loss in the six months to September 30 halves to GBP31.6 million from GBP62.2 million the year prior. Basic and diluted loss per share totals 4.77 pence, compared to 5.72p. Says value of investments was GBP99.6 million as at September 30, down from GBP194.1 million the year before.

----------

Metals Exploration PLC - Philippines-focused gold producer - Makes last payment due to the lenders under the mezzanine debt facilities on Monday on the basis of the lower interest rate of 7%, as opposed to 15%, which the company believes should apply under such facilities. Says amount outstanding on the group's senior facility as at Monday stands at USD2,629. Metals Exploration says it has agreed the 7% rate with the majority mezzanine lender, MTL Luxembourg SA. But explains it has been unable to reach agreement as yet, with the minority 29% mezzanine debt lenders, Runruno Holdings Ltd and D & A Holdings Ltd. RHL Group advisers have stated their belief that the higher 15% rate is applicable, which potentially amounts to an additional USD1.9 million owed. But Metals exploration disputes this. Discussions continue. Intends to apply future free cash generated from operations to fund ongoing growth opportunities based on MTL's proven operating track record in the Philippines.

----------

Allergy Therapeutics PLC - Sussex, England-based biotechnology company - Extends cash runway until the first quarter of 2025 following talks with major shareholders SkyGem Acquisition Ltd and Southern Fox Investments Ltd. Lenders agree that a further GBP15 million from the existing GBP40 million amended loan facility, announced on December 27, may be drawn down from the second quarter of 2024. Further, will issue warrants to the lenders following each drawdown under the amended loan facility, entitling the holders to subscribe for new shares at a price of 4 pence each. The entitlement to warrants will be 25 warrants for each GBP1 drawn down under the amended loan facility with a maximum of 1.00 billion warrants. The warrants will be exercisable in whole or in part from July 1 until January 15, 2027. Further, reports pretax loss in the six months to December 31 widens to GBP14.9 million from GBP8.2 million the year prior. Diluted loss per share totals 0.58p compared to LPS of 1.29p. Revenue falls to GBP33.6 million from GBP39.9 million. Explains the decrease in revenue is due to previously reported manufacturing capacity that needed to be allocated to investigational medicinal product batches for use in clinical trials and the ongoing programme of continuous improvement across the supply chain and quality systems paving the way for increased capacity. Demand for the company's products continues to be robust.

----------

Quartix Technologies PLC - Newtown, Wales-based vehicle tracking system provider - Issues trading statement ahead of Wednesday's annual general meeting. Says trading for the first two months of 2024 has been consistent with meeting market expectations for the year. Notes new unit subscriptions for the first quarter of 2024 are expected to be around 10% higher annually. Growth in new subscriptions continues to be led by France and Continental Europe. Further, advises Chief Financial Officer Emily Rees resigns to pursue opportunities outside the company.

----------

Microsaic Systems PLC - Surrey-based developer of real-time mass spectrometers - Reports that having passed quality control specifications, shipments of existing MicroTox reagent stock have begun to meet the demand from clients that are operating Modern Water instruments currently in service. Says stock levels are sufficient to meet this demand until restarted production output from the York facility passes testing and quality control for shipping, as scheduled for April. Further, agrees terms with GX Group, based in Usk Wales, for the continued manufacturing and further development of continuous toxicity monitoring instruments previously sold by the Modern Water business. Acting Executive Chair Bob Moore says: "The combination of Modern Water and Microsaic technologies is underway as planned."

----------

Kingfisher PLC - retailer which owns B&Q and Castorama - Instructs Goldman Sachs International to start the second tranche of the share buy back programme. This will start Wednesday and end no later than June 14. The maximum amount allocated to the tranche will be no greater than GBP50 million. Forms part of overall GBP300 million buy back.

----------

Solid State PLC - Redditch, England-based supplier & design-in manufacturer of computing, power, and communications products - Issues trading update to year ending March 31. Reports a record year with a strong trading performance towards the end of the year. Revenue and adjusted pretax profit are expected to be ahead of consensus expectations. This reflects the recognition of Systems revenue on deliveries in the current financial year. This had previously been expected to be recognised in the financial year to March 2025.

----------

Leeds Group PLC - West Yorkshire, England-based textile manufacturing company - Completes sale of Hemmers-Itex Textil Import Export GmbH. Explains the disposal is deemed to be a sale that divests the company of all, or substantially all of its trading businesses. Therefore, with effect from Tuesday, Leeds is regarded as an AIM Rule 15 cash shell.

----------

LPA Group PLC - Essex-based LED lighting and electro-mechanical systems maker - Issues trading statement at Wednesday's annual general meeting. States first quarter trading has been as anticipated. "Sales levels were largely on target, good order books remain and we are seeing an increased level of activity particularly." Cautions the second quarter "will be affected by late cable shipments which are now coming around the Cape but this will be made up in our third quarter." LPA says "it is clear that the return to profitability will be in our FY25 as some of the growth and profit we were planning for FY24 will have been deferred a further year."

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
26 Apr 2011 08:33

Allergy gets FDA lift

Shareholders in allergy vaccine developer Allergy Therapeutics were making hay Tuesday after the US Food and Drug Administration (FDA) signalled the imminent lifting of the clinical hold on three of the company's products. The FDA said the clinical hold on the Investigational New Drug applications

Read more
28 Mar 2011 17:03

London close: Flat day for FTSE 100

A second attempt to spring into life evaporated ahead of the close on Monday and the top share index finished just a few points higher. Worries that Japanese carmakers may have to suspend production at their plants in China following the earthquake disruption have sent copper prices lower. As a res

Read more
28 Mar 2011 14:57

London afternoon: Shares mark time

Footsie finished the morning clinging on to positive territory and not much changed over the lunch time trading session, with a mildly firmer start on Wall Street providing little additional impetus. Worries that Japanese carmakers may have to suspend production at their plants in China following t

Read more
28 Mar 2011 14:06

Weak German market hits sales at Allergy Therapeutics

Pharmaceutical firm Allergy Therapeutics reported broadly flat revenues and profits for the six months ended 31 December, as a result of weakness in its core German market. First half revenue was £27.4m, slightly higher than £27.3m in 2009. Weakness in the euro also had a £1.1m impact on turnover.

Read more
20 Sep 2010 14:41

Small caps: Allergy Therapeutics, Goldplat, Avacta

Hay fever treatment specialist Allergy Therapeutics posted an operating profit for the year to June of £1.5m (2009: loss £5.1m) and cut losses to £116,000 from £11.4m. "On the regulatory front, the submission in March 2009 of Pollinex Quattro Grass, our ultra-short course four injection grass alle

Read more
22 Jul 2010 12:36

Allergy Therapeutics Sees FY Revenue GBP40.7M, Operating Profit

LONDON (Dow Jones)--Allergy Therapeutics PLC (AGY.LN), a specialist pharmaceutical company focused on allergy vaccination, said Thursday, it expects to report revenue of GBP40.7 million, and an operating profit, for the year ended June 30, adding that the results was in-line with current market expe

Read more
1 Jul 2010 16:00

UK SMALLCAP ROUNDUP: Wills & Co Declared In Default

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps WILLS & CO STOCKBROKERS LTD, a small cap share dealer, has been declared to be in default by the Financial Services Compensation Scheme, four months afte

Read more
1 Jul 2010 12:57

UPDATE: Allergy Therapeutics Buys Swiss Co In Europe Push

(Adds analyst comment, detail.) By Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Drug developer Allergy Therapeutics PLC (AGY.LN) Thursday said it agreed to buy its Swiss distributor, in one of its first steps in a new strategy to bolster its position in Europe. Allergy sa

Read more
1 Jul 2010 10:17

Allergy Therapeutics Buys Teomed For GBP700,000

LONDON (Dow Jones)--Allergy Therapeutics PLC (AGY.LN) said Thursday it has agreed to acquire Teomed AG of Switzerland for a consideration of GBP700,000. MAIN FACTS: -The consideration for the acquisition of Teomed will comprise an initial cash payment of GBP500,000 on signing and a deferred

Read more
1 Jul 2010 10:04

Allergy Therapeutics Acquisition

TIDMAGY RNS Number : 6201O Allergy Therapeutics PLC 01 July 2010 ? Thursday 1 July 2010 Allergy Therapeutics plc ("Allergy Therapeutics" or "the Company") Allergy Therapeutics to acquire Teomed AG Expands Eur

Read more
24 Mar 2010 16:49

Cairn boss raises nearly £3m

Cairn Energy chief executive Sir Bill Gammell has raised nearly £3m from a share sale. Sir Bill sold 721,042 shares in the oil and gas producer and explorer at 414.4p each. He retains 3.21m shares, which is equivalent to 0.23% of the company's share capital. There have been two other sales by Si

Read more
1 Mar 2010 11:04

Small caps round-up: Beowulf, E2V, Mobile Doctors...

Beowulf, owner of several exploration projects in Sweden, continues to believe in the commercial prospects for its asset portfolio which has increased in both quantity and quality as well as resource type. Losses grew to £520,000 in 2009 from £399,000 the year before, but it says future price tren

Read more
22 Sep 2009 06:47

Tuesday tips round-up: Alliance Trust, MP Evans, Allergy Therapeutics

Alliance Trust's investment stance means that it is always in danger of trailing more heavily geared rivals when the stock market runs sharply ahead. However, on a rolling total return basis it continues to fare well ? ranked first out of its six largest peers over both one and two years. Further,

Read more
21 Sep 2009 08:04

Allergy Therapeutics narrows interim loss

Allergy vaccination group Allergy Therapeutics narrowed half year losses and said it is well placed to capitalise on the investments of the past. Pre-tax losses narrowed to £11.44m in the six month ended 30 June compared with a loss of £20.24m last time. Revenues increased by 22% to £37.8m, on a

Read more
9 Jul 2009 08:17

Small caps round-up: MBL, Netplay, Playtech...

Big profits and a maiden dividend have sent entertainment products distributor MBL charging higher Thursday. The supplier of CDs, DVDS and games reported a 42% hike in pre-tax profit for the year ended 31 March 2009 to £8.1m on revenue up 77.5% to £143.6m. Its major competitor, Entertainment UK, t

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.